MRNA vs. UTHR: Moderna vs. United Therapeutics Stock Comparison

November 11, 2026

How do Moderna (MRNA) and United Therapeutics (UTHR) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Moderna (MRNA) and United Therapeutics (UTHR) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Company profile comparison for Moderna (MRNA) and United Therapeutics (UTHR)
Profile Item	MRNA	UTHR
Name	Moderna Inc.	United Therapeutics Corporation
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Biotechnology
GICS Sub-Industry	Biotechnology	Biotechnology
Market Capitalization	101.48 billion USD	23.94 billion USD
Currency	USD	USD
Exchange	Nasdaq	Nasdaq
Listing Date	December 7, 2018	June 17, 1999
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

MRNA

UTHR

GSPC

Moderna (MRNA) vs. United Therapeutics (UTHR), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Moderna (MRNA) and United Therapeutics (UTHR). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Moderna (MRNA) and United Therapeutics (UTHR). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Moderna (MRNA) and United Therapeutics (UTHR)
Metric	MRNA	UTHR
Total Return (1Y)	1,031.66%	28.77%
Total Return (3Y, Annualized)	58.68%	37.63%
Total Return (5Y, Annualized)	3.23%	23.78%

Risk Profile

Drawdown History

MRNA

UTHR

GSPC

Moderna (MRNA) vs. United Therapeutics (UTHR), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Moderna (MRNA) and United Therapeutics (UTHR). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Moderna (MRNA) is heavily traded at around 21.61M shares per day, whereas United Therapeutics (UTHR) sees a more moderate 694.55K — larger orders in the latter may require more patience and tighter control over order sizing.

Risk profile metrics for Moderna (MRNA) and United Therapeutics (UTHR)
Metric	MRNA	UTHR
Volatility (1Y, Annualized)	194.88%	35.00%
Beta (5Y)	1.08	0.49
Max Drawdown (5Y)	-93.93%	-33.00%
Avg. Volume (3M)	21.61M	694.55K

Risk-Adjusted Performance

Risk-Return Positioning

MRNA and UTHR are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Moderna (MRNA) and United Therapeutics (UTHR)
Metric	MRNA	UTHR
Sharpe Ratio (1Y)	5.27	0.70
Sortino Ratio (1Y)	20.44	1.29

Profitability

ROE (TTM)

Moderna (MRNA) reports a negative ROE of -39.00%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile United Therapeutics (UTHR) reports 19.13%, ranking against industry peers normally.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

-39.00%

Max: 109.18%
Q3: 6.23%
Median: -26.66%
MRNA: -39.00%
Q1: -64.05%
Min: -167.77%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.13%

Max: 109.18%
UTHR: 19.13%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Moderna (MRNA) vs. United Therapeutics (UTHR): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Moderna (MRNA) reports a negative net margin of -141.43%, usually indicating a net loss over the period. Meanwhile United Therapeutics (UTHR) reports 38.61%, ranking against industry peers normally.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

-141.43%

Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%
MRNA: -141.43%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

38.61%

UTHR: 38.61%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Moderna (MRNA) vs. United Therapeutics (UTHR): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Moderna (MRNA) reports a negative operating margin of -557.93%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile United Therapeutics (UTHR) reports 28.99%, ranking against industry peers normally.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

-557.93%

Max: 83.12%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%
MRNA: -557.93%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

28.99%

Max: 83.12%
UTHR: 28.99%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Moderna (MRNA) vs. United Therapeutics (UTHR): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Moderna (MRNA) and United Therapeutics (UTHR)
Metric	MRNA	UTHR
ROE (TTM)	-39.00%	19.13%
ROA (TTM)	-13.26%	10.91%
Net Margin (TTM)	-141.43%	38.61%
Operating Margin (TTM)	-557.93%	28.99%
Gross Margin (TTM)	-66.02%	86.34%

Growth

Revenue Growth

United Therapeutics (UTHR) at 10.61% is around its peer norm for revenue growth, while Moderna (MRNA) at -39.92% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Moderna (MRNA) vs. United Therapeutics (UTHR): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: United Therapeutics (UTHR) reports EPS growth of 13.07%, ranked against its industry; Moderna (MRNA) has no EPS growth figure this period.

Moderna (MRNA) vs. United Therapeutics (UTHR): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Moderna (MRNA) and United Therapeutics (UTHR)
Metric	MRNA	UTHR
Revenue Growth (YoY)	-39.92%	10.61%
Revenue Growth (3Y CAGR)	-53.30%	18.02%
EPS Growth (YoY)	--	13.07%
EPS Growth (3Y CAGR)	--	22.92%

Financial Strength

Current Ratio (MRQ)

United Therapeutics (UTHR) at 4.61 keeps current ratio within its industry’s typical mid-range, while Moderna (MRNA) at 2.30 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for MRNA.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.30

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
MRNA: 2.30
Min: 0.10

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.61

Max: 25.13
Q3: 12.13
Median: 5.52
UTHR: 4.61
Q1: 2.47
Min: 0.10

Moderna (MRNA) vs. United Therapeutics (UTHR): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Only one side’s leverage can be read here: Moderna (MRNA) carries debt-to-equity ratio of 0.19 against its industry range, while United Therapeutics (UTHR) reports no figure this period.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.19

Max: 1.42
Q3: 0.65
MRNA: 0.19
Median: 0.15
Q1: 0.02
Min: 0.00

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00
UTHR: --

Moderna (MRNA) vs. United Therapeutics (UTHR): UTHR does not report debt-to-equity ratio, so it has no value marker; MRNA is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Financial Strength Metrics

Financial strength metrics for Moderna (MRNA) and United Therapeutics (UTHR)
Metric	MRNA	UTHR
Current Ratio (MRQ)	2.30	4.61
Debt / Equity (MRQ)	0.19	--
Net Debt / EBITDA	--	-1.53

Dividends

Dividend Yield (TTM)

Neither Moderna (MRNA) nor United Therapeutics (UTHR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MRNA: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

UTHR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Moderna (MRNA) vs. United Therapeutics (UTHR): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Moderna (MRNA) nor United Therapeutics (UTHR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MRNA: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

UTHR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Moderna (MRNA) vs. United Therapeutics (UTHR): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Moderna (MRNA) and United Therapeutics (UTHR)
Metric	MRNA	UTHR
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: United Therapeutics (UTHR) trades at 21.22 times trailing earnings, ranked against its peers, while Moderna (MRNA) has no P/E ratio this period.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
MRNA: --

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.22

Max: 85.34
Q3: 43.46
Median: 26.69
UTHR: 21.22
Q1: 13.30
Min: 0.07

Moderna (MRNA) vs. United Therapeutics (UTHR): MRNA does not report P/E ratio, so it has no value marker; UTHR is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

United Therapeutics (UTHR) at 7.51 is priced about in line with its industry on P/S ratio, while Moderna (MRNA) at 45.55 sits in the pricier quartile — MRNA costs more per dollar of sales.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

45.55

Max: 58.18
MRNA: 45.55
Q3: 25.77
Median: 7.30
Q1: 3.01
Min: 0.01

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.51

Max: 58.18
Q3: 25.77
UTHR: 7.51
Median: 7.30
Q1: 3.01
Min: 0.01

Moderna (MRNA) vs. United Therapeutics (UTHR): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

United Therapeutics (UTHR) at 3.80 is valued about in line with its industry on P/B ratio, while Moderna (MRNA) at 11.58 carries an above-peer premium to book — MRNA is pricier on assets.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

11.58

Max: 13.53
MRNA: 11.58
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.80

Max: 13.53
Q3: 6.54
UTHR: 3.80
Median: 3.25
Q1: 1.69
Min: -5.59

Moderna (MRNA) vs. United Therapeutics (UTHR): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Moderna (MRNA) and United Therapeutics (UTHR)
Metric	MRNA	UTHR
P/E Ratio (TTM)	--	21.22
P/S Ratio (TTM)	45.55	7.51
P/B Ratio (MRQ)	11.58	3.80
Free Cash Flow Yield (TTM)	0.29%	1.90%